CB-839, a selective glutaminase inhibitor, has anti-tumor activity in renal cell carcinoma and synergizes with everolimus and receptor tyrosine kinase inhibitors. (December 2016) - Emberley, E.; Bennett, M.; Chen, J.; Gross, M.; Huang, T.; Li, W.; Mackinnon, A.; Pan, A.; Rodriguez, M.; Steggerda, S.; Wang, T.; Zhang, J.; et al.